Who Needs Paxlovid in 2024? (2025)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy|Continue

JAMA

    Sign In

    Individual Sign In

    Sign inCreate an Account

    Access through your institution

    Sign In

    Purchase Options:

    Buy this article

    Subscribe to the JAMA journal

    This Issue

    Views 47,346

    Comments 3

    Medical News & Perspectives

    September 6, 2024

    RitaRubin,MA1

    JAMA. 2024;332(13):1040-1042. doi:10.1001/jama.2024.16432

    JAMA Medical News

    visual abstract icon Visual Abstract editorial comment icon Editorial Comment related articles icon Related Articles author interview icon Interviews multimedia icon Multimedia audio icon Listen to this article
    • Viewpoint COVID-19 Therapeutics for Nonhospitalized Older Adults

      PragnaPatel,MD, MPH; David E.Wentworth,PhD; DemetreDaskalakis,MD

      JAMA

    • Original Investigation Nirmatrelvir-Ritonavir and Symptoms of Postacute Sequelae of SARS-CoV-2 Infection

      Linda N.Geng,MD, PhD; HectorBonilla,MD; HaleyHedlin,PhD; Karen B.Jacobson,MD; LuTian,DSc; PrasannaJagannathan,MD; Phillip C.Yang,MD; Aruna K.Subramanian,MD; Jane W.Liang,PhD; SaShen,PhD; YaoweiDeng,MA; Blake J.Shaw,MS; BrenBotzheim,MS; ManishaDesai,PhD; DivyaPathak,MS; YasminJazayeri,MPH; DanielThai,BS; AndrewO’Donnell,MA; SukanyaMohaptra,BS; ZenitaLeang,BS; Gabriella Z. M.Reynolds,BS; Erin F.Brooks,MS; Ami S.Bhatt,MD, PhD; Robert W.Shafer,MD; Mitchell G.Miglis,MD; TomQuach; AnushriTiwari; AninditaBanerjee,PhD; Rene N.Lopez,MPH; MagdiaDe Jesus,PhD; Lawrence R.Charnas,MD, PhD; Paul J.Utz,MD; UpinderSingh,MD

      JAMA Internal Medicine

    Podcast (15:36)

    September 2024 Medical News Summary

    1x

    0:00 / 0:00

    Full Text

    As another COVID-19 summer surge hit the US this year, many infected people likely were prescribed the antivirals nirmatrelvir and ritonavir, better known as Paxlovid, for the first time. Or for the fourth time. Or somewhere in between.

    Nirmatrelvir-ritonavir, the only approved oral therapy for COVID-19, is recommended for treating mild to moderate SARS-CoV-2 infections among people who are at high risk of progression to severe disease. This includes people aged 50 years or older, especially those 65 years or older, as well as younger individuals who have any of a long list of comorbidities that increase the risk of severe COVID-19.

    Full Text

    Add or change institution

    Comment

    3 Comments for this article

    EXPAND ALL

    September 7, 2024

    Par for the course

    Nik MANASSIEV, MD | QGPSC

    I read most, but not all of the 'real world' studies. Those which I read, including studies from Hong Kong and Israel are open to bias. Please note the following comment in the article:

    “We remain very confident in Paxlovid’s clinical effectiveness at preventing severe outcomes, including hospitalization and death, from COVID-19 in patients at high risk of severe disease,” Pfizer spokesperson Kit Longley said in an early August email.

    The statement is par for the course. I am yet to see an employee of a drug company stating that their treatment is ineffective. Even less so if

    the treatment generates billions in revenue. Why would N3C member support Paxlovid is a mystery to me. There may be a small selected population, over 75s, immunosuppressed, and so on where Paxlovid may help. With rest, we are simply wasting money and resources.

    CONFLICT OF INTEREST: None Reported

    READ MORE

    September 6, 2024

    Paxlovid shows weak to no benefit

    Richard Foulkes, MD |

    Pfizer took a 5.6 billion(!) write off on returned Paxlovid in 2023. Of course depite this they had a revenue growth of 6%. Here we see very weak evidence for the benefit of Paxlovid with the best argument of no long Covid likely only appearing because it is rare to begin with and falls below sample size.

    CONFLICT OF INTEREST: None Reported

    September 6, 2024

    Unveiling a Systemic Bias in Paxlovid Research Reporting

    Eric Widera, MD | Universirt of California San Francisco

    The article “The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits” has a surprising but unfortunately very expected omission in the summary of the evidence for nirmatrelvir–ritonavir (Paxlovid) – the lack of any discussion of the Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR) study.(1) EPIC-SR is one of only two randomized control trials of nirmatrelvir-ritonavir to treat symptomatic patients with COVID-19, and the only study of standard-risk unvaccinated and high-risk vaccinated adult participants with COVID-19. Importantly, EPIC-SR failed to show a significant difference in the primary endpoint of the time to sustained alleviation of all COVID–19–related signs or symptoms between the nirmatrelvir–ritonavir group and the placebo group.

    While one may attribute this as an oversight, the omission of the EPIC-SR study is commonly seen both in the lay press and in academic publications. For example, an updated rapid living practice point published by the American College of Physicians (ACP) aimed to summarize the latest evidence on the use of treatments for COVID-19 in the outpatient setting made no mention of EPIC-SR.(2) At first glance, the omission of EPIC-SR appears to be appropriate given that EPIC-SR was published in April of 2024, and the inclusion criteria of the latest update to the rapid living practice points include studies published up until 15 November 2023. However, the results of EPIC-SR were first reported in a company press release on December 14, 2021 and posted on clinical clinicaltrials.gov in August of 2023.

    Selective publication and delayed reporting are important sources of bias in systematic literature reviews and are a well-known phenomenon seen in studies sponsored by pharmaceutical companies. Multiple studies have shown that studies with negative results, like EPIC-SR, are not only less likely to be published but also take longer than studies with positive results to be posted on ClinicalTrials.gov or published in a peer-reviewed medical journal.(3-5) It should be of no surprise that as opposed to the significant delay seen in the publication of EPIC-SR, the positive trial in high-risk patients (EPIC-HR) was complicated on September 9th, 2021 and was published 5 months later in February of 2022.

    Delayed reporting of trial can skew the perceived effectiveness of treatments like Paxlovid, underscoring the need for timely dissemination of all clinical trial data.

    References

    1.    Hammond J, Fountaine RJ, Yunis C, et al. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med. 2024;390(13):1186-1195. doi:10.1056/NEJMoa2309003
    2.    Qaseem A, Yost J, Abraham GM, et al. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2023;176(10):1396-1404. doi:10.7326/M23-1636
    3.    Qunaj L, Jain RH, Atoria CL, Gennarelli RL, Miller JE, Bach PB. Delays in the publication of important clinical trial findings in oncology. JAMA Oncol. 2018;4(7):e180264. doi:10.1001/jamaoncol.2018.0264
    4.    Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-260. doi:10.1056/NEJMsa065779
    5.    Manzoli L, Flacco ME, D’Addario M, et al. Non-publication and delayed publication of randomized trials on vaccines: survey. BMJ. 2014;348:g3058. doi:10.1136/bmj.g3058

    CONFLICT OF INTEREST: None Reported

    READ MORE

    Read More About

    Coronavirus (COVID-19)

    Download PDF Full Text

    Cite This

    Citation

    Rubin R. The Latest Research About Paxlovid: Effectiveness, Access, and Possible Long COVID Benefits. JAMA. 2024;332(13):1040–1042. doi:10.1001/jama.2024.16432

    Manage citations:

    Ris (Zotero) EndNote BibTex Medlars ProCite RefWorks Reference Manager Mendeley

    © 2024

    Comment

    Add or change institution

    JAMA+ AI

    Others Also Liked

    Select Your Interests

    Customize your JAMA Network experience by selecting one or more topics from the list below.

    • Academic Medicine
    • Acid Base, Electrolytes, Fluids
    • Allergy and Clinical Immunology
    • American Indian or Alaska Natives
    • Anesthesiology
    • Anticoagulation
    • Art and Images in Psychiatry
    • Artificial Intelligence
    • Assisted Reproduction
    • Bleeding and Transfusion
    • Cardiology
    • Caring for the Critically Ill Patient
    • Challenges in Clinical Electrocardiography
    • Climate and Health
    • Climate Change
    • Clinical Challenge
    • Clinical Decision Support
    • Clinical Implications of Basic Neuroscience
    • Clinical Pharmacy and Pharmacology
    • Coaching
    • Complementary and Alternative Medicine
    • Consensus Statements
    • Coronavirus (COVID-19)
    • Critical Care Medicine
    • Cultural Competency
    • Dental Medicine
    • Dermatology
    • Diabetes and Endocrinology
    • Diagnostic Test Interpretation
    • Digital Health
    • Drug Development
    • Electronic Health Records
    • Emergency Medicine
    • End of Life, Hospice, Palliative Care
    • Environmental Health
    • Equity, Diversity, and Inclusion
    • Ethics
    • Facial Plastic Surgery
    • Gastroenterology and Hepatology
    • Genetics and Genomics
    • Genomics and Precision Health
    • Geriatrics
    • Global Health
    • Guide to Statistics and Methods
    • Guidelines
    • Hair Disorders
    • Health Care Delivery Models
    • Health Care Economics, Insurance, Payment
    • Health Care Quality
    • Health Care Reform
    • Health Care Safety
    • Health Care Workforce
    • Health Disparities
    • Health Inequities
    • Health Policy
    • Health Systems Science
    • Hematology
    • History of Medicine
    • Humanities
    • Hypertension
    • Images in Neurology
    • Implementation Science
    • Infectious Diseases
    • Innovations in Health Care Delivery
    • JAMA Forum
    • JAMA Infographic
    • Law and Medicine
    • Leading Change
    • Less is More
    • LGBTQIA Medicine
    • Lifestyle Behaviors
    • Medical Coding
    • Medical Devices and Equipment
    • Medical Education
    • Medical Education and Training
    • Medical Journals and Publishing
    • Melanoma
    • Mobile Health and Telemedicine
    • Narrative Medicine
    • Nephrology
    • Neurology
    • Neuroscience and Psychiatry
    • Notable Notes
    • Nursing
    • Nutrition
    • Nutrition, Obesity, Exercise
    • Obesity
    • Obstetrics and Gynecology
    • Occupational Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otolaryngology
    • Pain Medicine
    • Palliative Care
    • Pathology and Laboratory Medicine
    • Patient Care
    • Patient Information
    • Pediatrics
    • Performance Improvement
    • Performance Measures
    • Perioperative Care and Consultation
    • Pharmacoeconomics
    • Pharmacoepidemiology
    • Pharmacogenetics
    • Pharmacy and Clinical Pharmacology
    • Physical Medicine and Rehabilitation
    • Physical Therapy
    • Physician Leadership
    • Poetry
    • Population Health
    • Primary Care
    • Professional Well-being
    • Professionalism
    • Psychiatry and Behavioral Health
    • Public Health
    • Pulmonary Medicine
    • Radiology
    • Regulatory Agencies
    • Reproductive Health
    • Research, Methods, Statistics
    • Resuscitation
    • Rheumatology
    • Risk Management
    • Scientific Discovery and the Future of Medicine
    • Sexual Health
    • Shared Decision Making and Communication
    • Sleep Medicine
    • Sports Medicine
    • Stem Cell Transplantation
    • Substance Use and Addiction Medicine
    • Surgery
    • Surgical Innovation
    • Surgical Pearls
    • Teachable Moment
    • Technology and Finance
    • The Art of JAMA
    • The Arts and Medicine
    • The Rational Clinical Examination
    • Tobacco and e-Cigarettes
    • Toxicology
    • Translational Medicine
    • Trauma and Injury
    • Treatment Adherence
    • Ultrasonography
    • Urology
    • Users' Guide to the Medical Literature
    • Vaccination
    • Venous Thromboembolism
    • Veterans Health
    • Violence
    • Women's Health
    • Workflow and Process
    • Wound Care, Infection, Healing

    Save Preferences

    Privacy Policy | Terms of Use

    X

    .

    ×

    Access your subscriptions

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Get full journal access for 1 year

    Get unlimited access and a printable PDF ($40.00)—
    Sign in or create a free account

    Rent this article from DeepDyve

    Access your subscriptions

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Get full journal access for 1 year

    Get unlimited access and a printable PDF ($40.00)—
    Sign in or create a free account

    Rent this article from DeepDyve

    Sign in to access free PDF

    Add or change institution

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Save your search

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Purchase access

    Customize your interests

    Free access to newly published articles

    To register for email alerts, access free PDF, and more

    Create a personal account or sign in to:

    • Register for email alerts with links to free full-text articles
    • Access PDFs of free articles
    • Manage your interests
    • Save searches and receive search alerts

      Privacy Policy

      Make a comment

      Free access to newly published articles

      To register for email alerts, access free PDF, and more

      Create a personal account or sign in to:

      • Register for email alerts with links to free full-text articles
      • Access PDFs of free articles
      • Manage your interests
      • Save searches and receive search alerts

        Privacy Policy

        Who Needs Paxlovid in 2024? (2025)

        References

        Top Articles
        Latest Posts
        Recommended Articles
        Article information

        Author: Nathanael Baumbach

        Last Updated:

        Views: 5545

        Rating: 4.4 / 5 (55 voted)

        Reviews: 94% of readers found this page helpful

        Author information

        Name: Nathanael Baumbach

        Birthday: 1998-12-02

        Address: Apt. 829 751 Glover View, West Orlando, IN 22436

        Phone: +901025288581

        Job: Internal IT Coordinator

        Hobby: Gunsmithing, Motor sports, Flying, Skiing, Hooping, Lego building, Ice skating

        Introduction: My name is Nathanael Baumbach, I am a fantastic, nice, victorious, brave, healthy, cute, glorious person who loves writing and wants to share my knowledge and understanding with you.